Safety and pharmacokinetics of single oral and intravenous doses of fluconazole in healthy subjects
- PMID: 2379224
Safety and pharmacokinetics of single oral and intravenous doses of fluconazole in healthy subjects
Abstract
At intervals of two to four weeks, eight subjects received 25 mg of fluconazole orally; 50 mg orally; 25 mg intravenously; 50 mg intravenously; and then 100 mg orally (six subjects). Physical examinations and laboratory tests performed before and after each drug administration revealed no side effects or significant changes in test results. After oral administration, plasma fluconazole levels rose rapidly in a dose-dependent manner, maximum levels being reached in 0.7 hours after 25 mg, in 1.4 hours after 50 mg, and in 1.7 hours after 100 mg. After intravenous administration, mean plasma drug levels were higher than after oral administration for 30 minutes and then declined rapidly; at one hour after injection, plasma levels were similar to those seen after oral administration. During 120 hours after oral administration, 69% of the 25-mg dose, 66% of the 50-mg dose, and 75% of the 100-mg dose were recovered unchanged in urine; after intravenous injection, 74% of the 25-mg dose and 72% of the 50-mg dose were recovered. The half-life of fluconazole was 31 to 37 hours after oral and intravenous administration. Calculations of the areas under the plasma fluconazole time curves showed a clear dose-dependent response. The results indicate that fluconazole is a safe and effective antifungal agent.
Similar articles
-
Pharmacokinetics of fluconazole after oral administration of single and multiple doses in African grey parrots.Am J Vet Res. 2006 Mar;67(3):417-22. doi: 10.2460/ajvr.67.3.417. Am J Vet Res. 2006. PMID: 16506902 Clinical Trial.
-
Pharmacokinetics and safety of Fosfluconazole after single intravenous bolus injection in healthy male Japanese volunteers.J Clin Pharmacol. 2004 Mar;44(3):284-92. doi: 10.1177/0091270003262799. J Clin Pharmacol. 2004. PMID: 14973307 Clinical Trial.
-
A randomized, open-label pharmacokinetic comparison of two oral formulations of fluconazole 150 mg in healthy adult volunteers.Clin Ther. 2005 Oct;27(10):1588-95. doi: 10.1016/j.clinthera.2005.10.016. Clin Ther. 2005. PMID: 16330294 Clinical Trial.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Pharmacokinetics and tissue penetration of fluconazole in humans.Rev Infect Dis. 1990 Mar-Apr;12 Suppl 3:S318-26. doi: 10.1093/clinids/12.supplement_3.s318. Rev Infect Dis. 1990. PMID: 2184510 Review.
Cited by
-
Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database.Front Pharmacol. 2022 Apr 28;13:891336. doi: 10.3389/fphar.2022.891336. eCollection 2022. Front Pharmacol. 2022. PMID: 35571077 Free PMC article.
-
Oral Candidosis: Pathophysiology and Best Practice for Diagnosis, Classification, and Successful Management.J Fungi (Basel). 2021 Jul 13;7(7):555. doi: 10.3390/jof7070555. J Fungi (Basel). 2021. PMID: 34356934 Free PMC article. Review.
-
Physiologically Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life Support: Fluconazole in Children on ECMO.CPT Pharmacometrics Syst Pharmacol. 2018 Oct;7(10):629-637. doi: 10.1002/psp4.12338. Epub 2018 Aug 13. CPT Pharmacometrics Syst Pharmacol. 2018. PMID: 30033691 Free PMC article.
-
Developmental changes of fluconazole clearance in neonates and infants in relation to ontogeny of glomerular filtration rate: literature review and data analysis.J Pharm Health Care Sci. 2018 Mar 20;4:5. doi: 10.1186/s40780-018-0103-5. eCollection 2018. J Pharm Health Care Sci. 2018. PMID: 29568540 Free PMC article.
-
Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers.Can J Hosp Pharm. 2009 Nov;62(6):457-63. doi: 10.4212/cjhp.v62i6.843. Can J Hosp Pharm. 2009. PMID: 22478933 Free PMC article.